NHS

News

NICE backs AZ’s Calquence for new use in leukaemia

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated

Views & Analysis

Pharma must adapt to embrace the opportunities of a new-look...

Fundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to adapt to this new way of working.

Views & Analysis

Inside the UK’s leading efforts to restart clinical research

A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework.

News

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK gene fusion mutations, regardless of where they o

News

NICE says no to AZ’s Lynparza for prostate cancer

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.

News

Lilly’s Olumiant is first JAK drug backed by NICE for eczema

Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known a

NICE backs AZ’s Calquence for new use in leukaemia

Pharma must adapt to embrace the opportunities of a new-look...

Inside the UK’s leading efforts to restart clinical research

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

NICE says no to AZ’s Lynparza for prostate cancer

Lilly’s Olumiant is first JAK drug backed by NICE for eczema

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

NHS

Editor's Picks